Aravive (Aravive) Float Percentage Of Total Shares Outstanding : 61.57% (As of Apr. 30, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Aravive Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aravive's float shares is 45.29 Mil. Aravive's total shares outstanding is 73.56 Mil. Aravive's float percentage of total shares outstanding is 61.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aravive's Insider Ownership is 7.63%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aravive's Institutional Ownership is 3.16%.

Aravive Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Aravive's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	45.29	/	73.56
	=	61.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aravive (Aravive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

VE11:Germany VE11:Germany

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Executives

Maria Carolina Petrini	officer: Chief Commercial Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard	officer: Chief Financial Officer	322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove	officer: Chief Operating Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia	director, 10 percent owner	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre	officer: Chief Scientific Officer	C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk	director	225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah	officer: Chief Financial Officer	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc	director	319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman	director	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani	director, officer: President and CEO	3928 POINT EDEN WAY, HAYWARD CA 94545